PPSS Group Launch Cut-Tex PRO Cut Resistant Fabric In Black Colour
Following several years of extensive research and development, UK based PPSS Group have today launched a highly anticipated black version of their high performance cut resistant fabric Cut-Tex PRO.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200317005055/en/
PPSS Group's CEO showcasing first production sample of his firm's black Cut-Tex PRO cut resistant fabric (Photo: Business Wire)
Robert Kaiser, CEO of PPSS Group said: “Cut-Tex PRO is a thoroughly field-tested cut resistant fabric, used to manufacture potentially lifesaving slash and cut resistant clothing for law enforcement and other homeland security professionals.”
“The most common question we have faced over the past years is: Can you also produce it in a much darker colour? From today onwards we can now answer this question with: Yes, we can!”
Frontline professionals dealing with potentially aggressive, hostile or intoxicated members of the public are at risk of being attacked with edged weapon, knives, razor blades and broken glass.
Cut-Tex PRO enables uniform, workwear and tactical apparel manufacturers to incorporate a dependable and ultra-durable cut resistant fabric into their garment designs to help protect their clients and customers.
Protecting especially kay arteries and blood vessels means effectively preventing lacerations, cuts and subsequent rapid blood loss, shock and ultimately loss of valuable life.
Cut-Tex PRO is a knitted cut resistant fabric, not much thicker than a normal T-Shirt and very soft to touch.
At pH 6.6, Cut-Tex PRO has a pH value similar to that of water. This makes it an extremely low risk skin irritation fabric.
It offers EN 388:2016 cut resistance level E and level 5 based on the previous EN 388:2003 standard. It has also been tested and certified to ANSI/ISEA 2016 cut resistance level A5.
Cut-Tex PRO is available in individual rolls. Each roll is 25m long and 80cm wide. When cut open the fabric is 1.6m wide.
The MOQ for the black version is 12 rolls, equalling 1 standard pallet.
The fabric is only available for purchase directly from PPSS Group. In case you have any questions, please contact the relevant department of the company directly: info@cut-tex.com
About PPSS Group
PPSS Group is an international firm, dedicated to the design, manufacture and supply of high-performance protective clothing, offering protection from edged weapons, blunt force trauma, hypodermic needles and human bites. PPSS Group is also behind the SlashPRO Slash Resistant Clothing brand.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200317005055/en/
Contact information
Media Contact:
Ryan Vickers – Chief Revenue Officer (CRO)
E: info@ppss-group.com
T: +44 (0) 845 5193953
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
Incyte Japan Announces Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer22.12.2025 08:42:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC). "Today's approval marks a significant milestone for patients with advanced anal cancer in Japan – the MHLW’s approval of Zynyz as the first and only first-line treatment for SCAC," said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan G.K. "By offering combination therapy with chemotherapy, Zynyz provides a vital new path forward for patients facing this challenging disease, addressing a significant unmet need in cancer care for patients with SCAC and their families." The approval was based on data from the Phase 3 POD1UM-303/InterAACT2 trial evaluating Zynyz in combination with platinum-based chemotherapy (carboplatin-paclitaxel) in adult patients with metastatic or inoperable
GBC AG Analyst Coverage Report on Mexedia S.p.A. Società Benefit Completed and Published22.12.2025 08:30:00 CET | Press Release
Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” or the “Company”) informs that the analyst coverage report prepared by GBC AG – one of the leading independent financial research firms in Germany –, developed within an issuer-sponsored research framework, has been completed and is now publicly available. The report follows the re-initiation of analyst coverage by GBC AG previously communicated by the Company and is based exclusively on publicly available information. The content, assumptions and conclusions of the report are solely attributable to the analyst. The GBC AG analyst coverage report is available on the Company’s official website at the following address: https://mexedia.com/en/financial-statements-and-reports/ and on the analyst’s website. Daniel Gilcher, Chief Financial Officer of Mexedia S.p.A. Società Benefit, stated: “The completion and publication of the analyst coverage report by GBC AG represents the conclus
Hisense Joins HEVC Advance Patent Pool22.12.2025 03:06:00 CET | Press Release
Access Advance LLC, the global leader in video codec patent pool licensing, today announced that Hisense Group Holdings Co., Ltd. has joined the HEVC Advance Patent Pool as a Licensee. Hisense joins the recent additions to the Access Advance patent pools, including Xiaomi, MSI, Transsion, and expanded relationships with Huawei, HP and Sharp. Hisense, headquartered in Qingdao, China, is one of the world's largest television manufacturers, with a global presence spanning Asia, Europe, the Americas, and beyond. The company's products reach consumers in more than 160 countries and regions worldwide. "We are pleased to welcome Hisense to the HEVC Advance Patent Pool," said Peter Moller, CEO of Access Advance. "This agreement is the result of extensive engagement between our teams over a considerable period of time. Hisense's decision to join the pool reflects a recognition that transparent, efficient licensing solutions benefit both innovators and implementers across the video technology ec
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom